who owns tirzepatide Compounded Weight Loss Program | GLP-1 Treatment Compound Tirzepatide

Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update

By Anna Greene, PhD, NETRF Chief Scientific Officer Drugs like Ozempic, Wegovy, and Mounjaro, known as GLP-1 receptor agonists, are now widely used to treat type 2 diabetes and obesity

Discover how microdosing with GLP-1 meds can manage appetite and support blood sugar

In spring 2025, the Food and Drug Administration (FDA) resolved and ended the GLP-1 medications shortage, subsequently releasing declaratory orders that neither outsourcing compounding pharmacies or pharmacies could compound drugs that were essentially copies of either semaglutide (available under the brand names Ozempic, Rybelsus, and Wegovy) and tirzepatide (available under the brand names Mounjaro, and Zepbound).

Semaglutide timing matters for effectiveness and side effect management

Formulated in MCT oil for SubQ administration, Andrenyx is available in 50 mg, 75 mg, and 100 mg doses, supplied in packs of 4 single-dose syringes